

## Dear Friends and Protagen Collaborators,

What a year it was! In our pharma collaboration business we are now working with five of the top 10 pharma companies, and have further expanded our NavigAID product line. We also launched three CE marked IVD Assays and out-licensed our proprietary BICD2 marker to the global market leader Inova Diagnostics. Thus, it is fair to say that we were keeping busy and you can expect more of the same in 2017. We are expanding into immuno-oncology and will focus on commercializing our offering and products for better personalized treatment strategies for cancer and autoimmune disease patients.



### NavigAID Product Family: SSc Launch and more



In December we launched our latest addition to the NavigAID product family, NavigAID SSc (a corresponding whitepaper can be found on our website). SSc is an autoimmune disease with significant mortality and limited therapeutic options. The NavigAID SSc array enables the distinct segregation of patient subgroups, thereby increasing the probability of success in both SSc treatment and clinical drug development. In 2017 we intend to add more NavigAID products to our portfolio for RA, Sjögren's and Immuno-Oncology.

### Conferences & Meet us @



Last quarter we attended BIOEurope, the Annual Meeting of the Society for Immunotherapy in Cancer (SITC), and the American College of Rheumatology (ACR) Annual Meeting, alongside a number of smaller conferences. We presented five posters at ACR, the most important scientific conference in the autoimmune disease field. Our attendance at SITC documents our expansion into immuno-oncology. This month, we are attending the JP Morgan Healthcare Conference in San Francisco and look forward to meeting you there.

### Corporate News & PR



Throughout the year we have continued to build on our visibility. During the last quarter we published three press releases, several editorials (including those published in GEN and TZDo), and our NavigAID SSc whitepaper. We also gave oral presentations at the Munich Biomarker Conference and the German Equity Forum in Frankfurt. Protagen has established itself as a trusted partner in autoimmune diagnostics and patient stratification and is now expanding its approach into immuno-oncology.

## Quartely Update

In 2016 we raised the bar once more, with four product launches it was easily our best year to date. During the year, we made some structural refinements to lay the foundations for sustainable, continued commercial success and for gearing up the company for 2017 and

beyond. Management and Supervisory Board changes were implemented and our strategy was adapted, paving the way for an expansion into immuno-oncology and an even greater focus on the US market.

Our NavigAID concept is now well established

and there is increasing demand for similar products in other indications. Thus, we plan to do our best to comply with those demands, making additions to the NavigAID product line a priority in the new year, which promises to be truly exciting!

## News

### Protagen Launches NavigAID Assay to Support Clinical Drug Development for Autoimmune Diseases

Protagen AG today announced the launch of NavigAID SSc, a disease stratification assay designed to support pharmaceutical and biotechnology companies with their Systemic Sclerosis (SSc) drug development efforts.

[READ MORE](#)

### Protagen AG successfully joined forces with Novartis

Protagen AG, a leading provider of pharma development services, novel diagnostic tests and companion diagnostics in the fields of immuno-oncology and autoimmune disease, today announced the successful completion a collaboration agreement with Novartis Pharma AG.

[READ MORE](#)

### Finally – Fireworks

So who did it better this year? In 2016 Sydney splashed out a record \$7 million on its 'biggest and best' New Year's fireworks display while London exploded in color with 12,000 crackers over Big Ben. The show cost £1.8 million and lasted 11 minutes. If you did better than that please let us know. Wishing you a cracking 2017!

